FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310160992> ?p ?o ?g. }

• W4310160992 endingPage "1511" @default.
• W4310160992 startingPage "1509" @default.
• W4310160992 abstract "Introduction: Systemic mastocytosis (SM) is a rare myeloid neoplasm driven by the KIT D816V mutation in ~95% of patients. Patients with advanced SM (AdvSM) have a poor prognosis and treatment options are limited. Avapritinib, an oral, potent, highly selective inhibitor of KIT D816V, is approved in the USA for treatment of adults with AdvSM, and in Europe after ≥1 prior systemic therapy. Avapritinib is not recommended for the treatment of patients with AdvSM with platelet counts <50×109/L. Data from the multi-center, international, phase 1 EXPLORER (NCT02561988) and phase 2 PATHFINDER (NCT03580655) clinical studies demonstrated that responses to avapritinib treatment were rapid, deep, and durable regardless of prior therapy, AdvSM subtype, or presence of high-risk mutations. Here we present analyses from patients with AdvSM treated with avapritinib as first-line therapy in PATHFINDER. Methods: Analyses included adult patients with centrally confirmed AdvSM without prior antineoplastic treatment for AdvSM (treatment-naïve) who initiated 200 mg once-daily avapritinib in the PATHFINDER study. The primary endpoint was overall response rate (ORR), centrally evaluated according to the modified International Working Group-Myeloproliferative Neoplasms Research and Treatment-European Competence Network on Mastocytosis (mIWG-MRT-ECNM) response criteria defined as complete remission with full (CR) or partial (CRh) recovery of peripheral blood counts, partial remission (PR), or clinical improvement (CI). Secondary endpoints included, but were not limited to, mean change from baseline measures of disease burden (bone marrow mast cell [BM MC] burden, serum tryptase, blood KIT D816V variant allele fraction [VAF], and spleen volume), duration of response (DOR), time to response (TTR), overall survival (OS) and safety. Results: As of April 20, 2021, 107 patients with centrally confirmed AdvSM were enrolled, of whom 38 were treatment-naïve; 18% (n=7/38) had ASM, 74% (n=28/38) SM-AHN, and 8% (n=3/38) MCL. Median age (range) was 68 years (39-88), 53% were male, 16% had Eastern Cooperative Oncology Group performance status 2-3, and 95% exhibited KIT D816V. In 25 of 38 (66%) mIWG-MRT-ECNM response-evaluable patients, the ORR (95% CI) was 84% (n=21/25; 64-96) with 32% (n=8/25) achieving CR or CRh, 48% (n=12/25) achieving PR, and 4% (n=1/25) CI (Table). The median TTR (range) was 2.0 months (0.3-12.2). Median DOR across all subtypes was not reached at the time of analysis; however, the DOR rate (95% CI) was 100% (100-100) at 12 months and 86% (60-100) at 18 months. For patients with ASM, the DOR rate was 100% (100-100) at 12 and 18 months. In patients with SM-AHN, the DOR rate was 100% (100-100) at 12 months and 83.3% (53.5-100) at 18 months. After a median follow-up of 9.7 months, median OS in all patients was not reached. The OS rate was 96% (95% CI: 87-100) at 12 months and 88% (95% CI: 71-100) at 24 months. The OS rate at 12 months was 100% for patients with ASM or MCL and 94% (84-100) for patients with SM-AHN. At 24 months, OS rate was 86% (67-100) for patients with SM-AHN. In almost all patients, reductions of ≥50% in measures of disease burden including reduction in BM MC burden (84%, n=32/38), serum tryptase (95%, n=36/38), KIT D816V VAF (89%, n=34/38), and ≥35% reduction in spleen volume (66%, n=25/38) were observed. Total clearance of neoplastic MC aggregates in BM was achieved in 63% of patients (n=24/38). The most frequent (≥25% of N=38) treatment-related adverse events (TRAEs) were (any grade, grade ≥3) periorbital edema (53%, 5%), thrombocytopenia (45%, 21%), peripheral edema (37%, 3%), and anemia (26%, 13%). In total, 7 (18%) patients experienced cognitive effects, all grade 1 or 2; no intracranial bleeding events and no treatment-related deaths were reported. 28 (74%) patients had dose reductions and 25 (66%) had dose interruptions due to TRAEs. Thrombocytopenia was the most common TRAE leading to dose reduction (21%, n=8/38) and dose interruption (26%, n=10/38). 4 (10%) patients discontinued treatment due to TRAEs; 1 discontinuation each was due to neutropenia, thrombocytopenia, cognitive effects, and worsening weight loss. Conclusions: Avapritinib demonstrated a high level of efficacy as the first-line therapy for patients with AdvSM across all disease subtypes with an ORR of 84% and an OS rate of 88% at 2 years. Avapritinib treatment with a 200 mg once-daily starting dose was generally well-tolerated. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310160992 created "2022-11-30" @default.
• W4310160992 creator A5006870473 @default.
• W4310160992 creator A5007755609 @default.
• W4310160992 creator A5015788207 @default.
• W4310160992 creator A5021124944 @default.
• W4310160992 creator A5027994767 @default.
• W4310160992 creator A5028061272 @default.
• W4310160992 creator A5049375028 @default.
• W4310160992 creator A5065621786 @default.
• W4310160992 creator A5074808453 @default.
• W4310160992 creator A5082924494 @default.
• W4310160992 creator A5085442439 @default.
• W4310160992 date "2022-11-15" @default.
• W4310160992 modified "2023-10-16" @default.
• W4310160992 title "Avapritinib As First-Line Therapy in Patients with Advanced Systemic Mastocytosis: Efficacy and Safety from the Pathfinder Clinical Study" @default.
• W4310160992 doi "https://doi.org/10.1182/blood-2022-166986" @default.
• W4310160992 hasPublicationYear "2022" @default.
• W4310160992 type Work @default.
• W4310160992 citedByCount "1" @default.
• W4310160992 countsByYear W43101609922023 @default.
• W4310160992 crossrefType "journal-article" @default.
• W4310160992 hasAuthorship W4310160992A5006870473 @default.
• W4310160992 hasAuthorship W4310160992A5007755609 @default.
• W4310160992 hasAuthorship W4310160992A5015788207 @default.
• W4310160992 hasAuthorship W4310160992A5021124944 @default.
• W4310160992 hasAuthorship W4310160992A5027994767 @default.
• W4310160992 hasAuthorship W4310160992A5028061272 @default.
• W4310160992 hasAuthorship W4310160992A5049375028 @default.
• W4310160992 hasAuthorship W4310160992A5065621786 @default.
• W4310160992 hasAuthorship W4310160992A5074808453 @default.
• W4310160992 hasAuthorship W4310160992A5082924494 @default.
• W4310160992 hasAuthorship W4310160992A5085442439 @default.
• W4310160992 hasBestOaLocation W43101609921 @default.
• W4310160992 hasConcept C121608353 @default.
• W4310160992 hasConcept C126322002 @default.
• W4310160992 hasConcept C16005928 @default.
• W4310160992 hasConcept C161191863 @default.
• W4310160992 hasConcept C185926286 @default.
• W4310160992 hasConcept C2778940482 @default.
• W4310160992 hasConcept C2780007613 @default.
• W4310160992 hasConcept C2780581156 @default.
• W4310160992 hasConcept C2994076244 @default.
• W4310160992 hasConcept C41008148 @default.
• W4310160992 hasConcept C530470458 @default.
• W4310160992 hasConcept C71924100 @default.
• W4310160992 hasConceptScore W4310160992C121608353 @default.
• W4310160992 hasConceptScore W4310160992C126322002 @default.
• W4310160992 hasConceptScore W4310160992C16005928 @default.
• W4310160992 hasConceptScore W4310160992C161191863 @default.
• W4310160992 hasConceptScore W4310160992C185926286 @default.
• W4310160992 hasConceptScore W4310160992C2778940482 @default.
• W4310160992 hasConceptScore W4310160992C2780007613 @default.
• W4310160992 hasConceptScore W4310160992C2780581156 @default.
• W4310160992 hasConceptScore W4310160992C2994076244 @default.
• W4310160992 hasConceptScore W4310160992C41008148 @default.
• W4310160992 hasConceptScore W4310160992C530470458 @default.
• W4310160992 hasConceptScore W4310160992C71924100 @default.
• W4310160992 hasIssue "Supplement 1" @default.
• W4310160992 hasLocation W43101609921 @default.
• W4310160992 hasOpenAccess W4310160992 @default.
• W4310160992 hasPrimaryLocation W43101609921 @default.
• W4310160992 hasRelatedWork W2009823773 @default.
• W4310160992 hasRelatedWork W2912404883 @default.
• W4310160992 hasRelatedWork W3026902890 @default.
• W4310160992 hasRelatedWork W3030437504 @default.
• W4310160992 hasRelatedWork W4287582753 @default.
• W4310160992 hasRelatedWork W4297184974 @default.
• W4310160992 hasRelatedWork W4310160992 @default.
• W4310160992 hasRelatedWork W4366142243 @default.
• W4310160992 hasRelatedWork W4386270979 @default.
• W4310160992 hasRelatedWork W4386281965 @default.
• W4310160992 hasVolume "140" @default.
• W4310160992 isParatext "false" @default.
• W4310160992 isRetracted "false" @default.
• W4310160992 workType "article" @default.